Answers are grounded in this paper and cite their sources.
The 22q11.2 deletion syndrome (22qDS) is a major genetic risk factor for schizophrenia (Sz). We found that iPSC-derived neurons (iNeurons) from 22qDS +Sz individuals exhibit weaker mitochondrial energetics, whereas iNeurons from individuals with the same deletion but no psychosis (22qDS -Sz) upregulate expression of mitochondrial biogenesis-related genes. Here, we investigated why the +Sz group fails to undergo this compensation, finding that 22qDS +Sz iNeurons have older and more depolarized mitochondria than 22qDS -Sz or controls. Transcriptomic and proteomic analyses revealed downregulation of mitophagy-related pathways, and live imaging revealed elevated lysosomal pH. Restoring lysosomal acidity with acidifying nanoparticles improved mitophagy and, remarkably, increased the expression of mitochondrial biogenesis-related transcription factors in the +Sz neurons. We conclude that lysosomal dysfunction and impaired mitophagy differentiate 22qDS individuals who develop schizophrenia from those who do not. Mitophagy could be a novel therapeutic or preventative opportunity for Sz in the context of genetic neurodevelopmental disorders.
No takes yet. Share an insight, caveat, or question.
Stronati et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: